ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
61 040,83
1,21%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Editas Medicine Inc (EDIT)

  7. Editas Medicine Inc (EDIT) Actualités

EDIT

Editas Medicine (EDIT)

Editas Medicine Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:EDIT
DateHeureSourceTitreSymboleSociété
14/06/202412h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EDITEditas Medicine Inc
14/06/202409h01GlobeNewswire Inc.Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual CongressNASDAQ:EDITEditas Medicine Inc
14/06/202409h00GlobeNewswire Inc.Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual CongressNASDAQ:EDITEditas Medicine Inc
06/06/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EDITEditas Medicine Inc
31/05/202422h21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EDITEditas Medicine Inc
10/05/202412h00GlobeNewswire Inc.Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:EDITEditas Medicine Inc
08/05/202422h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EDITEditas Medicine Inc
08/05/202414h29IH Market NewsU.S. Futures Slightly Dip Amid Corporate Earnings and Quiet Economic Calendar, Oil Prices FallNASDAQ:EDITEditas Medicine Inc
08/05/202413h00GlobeNewswire Inc.Editas Medicine Announces First Quarter 2024 Results and Business UpdatesNASDAQ:EDITEditas Medicine Inc
02/05/202413h00GlobeNewswire Inc.Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor EventsNASDAQ:EDITEditas Medicine Inc
01/05/202414h00GlobeNewswire Inc.Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell CollaborationNASDAQ:EDITEditas Medicine Inc
22/04/202422h31GlobeNewswire Inc.Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:EDITEditas Medicine Inc
28/02/202423h13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:EDITEditas Medicine Inc
28/02/202422h39Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EDITEditas Medicine Inc
28/02/202413h00GlobeNewswire Inc.Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business UpdatesNASDAQ:EDITEditas Medicine Inc
21/02/202413h00GlobeNewswire Inc.Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor EventsNASDAQ:EDITEditas Medicine Inc
14/02/202414h40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EDITEditas Medicine Inc
31/01/202415h00GlobeNewswire Inc.Editas Medicine to Participate in Upcoming Investor ConferencesNASDAQ:EDITEditas Medicine Inc
08/01/202414h15GlobeNewswire Inc.Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare ConferenceNASDAQ:EDITEditas Medicine Inc
03/01/202413h00GlobeNewswire Inc.Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EDITEditas Medicine Inc
13/12/202318h48Dow Jones NewsEditas Medicine Strikes License Deal With Vertex Pharmaceuticals -- UpdateNASDAQ:EDITEditas Medicine Inc
13/12/202315h49Dow Jones NewsEditas Medicine Strikes License Deal With Vertex PharmaceuticalsNASDAQ:EDITEditas Medicine Inc
13/12/202315h00GlobeNewswire Inc.Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9NASDAQ:EDITEditas Medicine Inc
11/12/202318h00GlobeNewswire Inc.Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored WebinarNASDAQ:EDITEditas Medicine Inc
03/11/202312h00GlobeNewswire Inc.Editas Medicine Announces Third Quarter 2023 Results and Business UpdatesNASDAQ:EDITEditas Medicine Inc
02/11/202314h12GlobeNewswire Inc.Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored WebinarNASDAQ:EDITEditas Medicine Inc
27/10/202313h00GlobeNewswire Inc.Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor EventsNASDAQ:EDITEditas Medicine Inc
16/10/202314h00GlobeNewswire Inc.Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell DiseaseNASDAQ:EDITEditas Medicine Inc
25/09/202322h30GlobeNewswire Inc.Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy OfficerNASDAQ:EDITEditas Medicine Inc
25/09/202315h00GlobeNewswire Inc.Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy OfficerNASDAQ:EDITEditas Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:EDIT

Dernières Valeurs Consultées

LSE
NV50
Citi Fun 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés